Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Xifaxan in Moderate to Severe Crohn's Disease
NCT00603616Phase 2Completed
- Sponsor
- Scott Lee
- Start
- Nov 2008
- Primary completion
- Nov 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of rifaximin in Crohn's disease, sponsored by Scott Lee. Primary endpoint: Clinical Response (> 100 point decrease in CDAI) at 8 weeks. Started Nov 2008; status: completed.
02
Drugs
rifaximin
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT00603616.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00603616.